Vnitr Lek 2016, 62(Suppl 6):78-83

Gitelman's syndrome as common cause of hypokalemia and hypomagnesemia

Romana Ryšavá1,*, Jana Reiterová1, Markéta Urbanová2, Jitka Štekrová2, Petr Lněnička2, Vladimír Tesař1
1 Nefrologická klinika 1. LF UK a VFN v Praze
2 Ústav biologie a lékařské genetiky 1. LF UK Praha

The Gitelman syndrome (GS) is an autosomal recessive disorder characterized by hypokalemic metabolic alkalosis and presence of hypocalciuria and hypomagnesemia. It is one of the most common congenital "salt-wasting" tubulopathies, where the impairment of function of the Na+-Cl- cotransporter (NCCT) in the distal convoluted tubule is primary and hypokalemia secondary. Hypomagnesemia is caused by the impairment of magnesium reabsorption through TRPM6 channel which is located just by NCCT. Clinically, patients suffer from fatigue and hypotension due to loss of salt and water and also have cramps and tetany. In some patients chondrocalcinosis can be identified which leads to protracted pain and repeated aseptic inflammations in the joints. The course of the disease, though, is typically benign, and it rarely leads to structural changes in the kidneys or renal impairment. In the period of 2004-2006 we commenced examination of patients with suspected GS based on clinical and laboratory findings within a grant project in the Czech Republic, and in the following years this methodology was introduced to the common laboratory practice. By the year 2011 we had identified 7 different causal mutations in the gene SLC12A3 (4 of them new) among the Czech population, which is responsible for the origin of this disease. The majority of patients, whose clinical findings indicated the presence of GS, had the mutation actually detected, specifically in heterozygous form; 4 individuals were then homozygous. Most of the identified mutations were missense mutations and the most common type found among the Czech population was the change 1315 G>A within the geneSLC12A3, which causes impairment of glycosylation of the NCCT transporter. Further a great number of single-nucleotide polymorphisms were found that may be involved in clinical manifestation of the disease.

Keywords: gene mutation; gene sequence; Gitelman's syndrome; NCC channel; PCR

Received: August 26, 2016; Accepted: October 5, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšavá R, Reiterová J, Urbanová M, Štekrová J, Lněnička P, Tesař V. Gitelman's syndrome as common cause of hypokalemia and hypomagnesemia. Vnitr Lek. 2016;62(Supplementum 6):78-83.
Download citation

References

  1. Bartter FC, Pronove P, Gill JR et al. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am J Med 1962; 33: 811-828. Go to original source... Go to PubMed...
  2. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Transactions Ass Am Phys 1966; 79: 221-235.
  3. Shibli AA, Narchi H. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J Methodol 2015; 5(2): 55-61. Dostupné z DOI: <http://dx.doi.org/10.5662/wjm.v5.i2.55>. Go to original source... Go to PubMed...
  4. Simon DB, Nelson-Willliams C, Bia MJ et al. Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genetics 1996; 12(1): 24-30. Go to original source... Go to PubMed...
  5. Takeuchi Y, Mishima E, Shima H et al. Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman Syndrome. J Am Soc Nephrol 2014; 26(6): 1-9. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2014030260>. Go to original source... Go to PubMed...
  6. Lin SH, Cheng NL, Hsu YJ et al. Intrafamiliar phenotype variability in patients with Gitelman syndrome having the same mutaitons in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 2004; 43(2): 304-312. Go to original source... Go to PubMed...
  7. Wang L, Dong Ch, Xi YG et al. Thiaside-sensitive Na+-Cl- contrasporter: genetic polymorphisms and human diseases. Acta Biochim Biophys Sin 2015; 47(5): 325-334. Dostupné z DOI: <http://dx.doi.org/10.1093/abbs/gmv020>. Go to original source... Go to PubMed...
  8. De Jong JC, Van der Vliet WA, Van den Heuvel L et al. Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman's syndrome. J Am Soc Nephrol 2002; 13(6): 1442-1448. Go to original source... Go to PubMed...
  9. Peters M, Jeck N, Reinalter S et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002; 112(3): 183-190. Go to original source... Go to PubMed...
  10. Knoers NVAM, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008; 3: 22. Dostupné z DOI: <http://dx.doi.org/10.1186/1750-1172-3-22>. Go to original source... Go to PubMed...
  11. Graziani G, Fedeli C, Moroni L et al. Gitelman syndrome: pathophysiological and clinical aspects. QJM 2010; 103(10): 741-748. Dostupné z DOI: <http://dx.doi.org/10.1093/qjmed/hcq123>. Go to original source... Go to PubMed...
  12. Tosi F, Bianda N, Truttmann AC et al. Normal plasma total magnesium in Gitelman syndrome. Am J Med 2004; 116(8): 573-574. Go to original source... Go to PubMed...
  13. Bianchetti MG, Bettinelli A, Casez JP et al. Evidence for disturbed regulation of calciotropic hormone metabolites in Gitelman syndrome. J Clin Endocrinol Metab 1995; 80(1): 224-228. Go to original source...
  14. Nijenhuis T, Vallon V, van der Kemp AW at al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channels abundance explains thiazide-induced hypocalciuria and hypomagnesemia. Clin Incevt 2005; 115(6): 1651-1658. Go to original source... Go to PubMed...
  15. Cruz DN, Shaer AJ, Bia MJ et al. Yale Gitelman's and Bartter's Syndrome Collaborative Study Group. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001; 59(2): 710-717. Go to original source... Go to PubMed...
  16. Foglia P, Bettinelli A, Tosetto C et al. Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). Nephrol Dial Transpl 2004; 19(6): 1398-1402. Go to original source... Go to PubMed...
  17. Chen YC, Yang WC, Yang AH et al. Primary Sjogren'S syndrome associated with Gitelman's syndrome presenting with muscular paralysis. Am J Kidney Dis 2003; 42(3): 586-590. Go to original source... Go to PubMed...
  18. Moustakakis MN, Bockorny M. Gitelman syndrome and pregnancy. Clin Kidney J 2012; 5(6): 552-555. Dostupné z DOI: <http://dx.doi.org/10.1093/ckj/sfs126>. Go to original source... Go to PubMed...
  19. Blanchard A, Vargas-Poussou R, Vallet M et al. Indomethacin, amiloride, or eplerenone for treating hypokalemia i Gitelman syndrome. J Am Soc Nephrol 2015; 26(2): 468-475. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2014030293>. Go to original source... Go to PubMed...
  20. Urbanová M, Reiterová J, Štekrová J et al. Genetic analysis of Gitelman's syndrome patients from the Czech republic and Slovakia - Three novel mutations found. Kidney and Blood Press Res 2006; 29(6): 360-365. Go to original source... Go to PubMed...
  21. Urbanová M, Reiterova J, Štektova J et al. DNA analysis of renal electrolyte transporter genes among patients suffering from Bartter and Gitelman syndromes - summary of mutation screening. Folia Biologica (Praha) 2011; 57(2): 65-73. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.